2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre Y, Clarke AE. Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. The Journal Of Rheumatology 2018, 45: 393-396. PMID: 29335347, PMCID: PMC5834350, DOI: 10.3899/jrheum.170652.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesFemaleHumansLung NeoplasmsLupus Erythematosus, SystemicMaleMiddle AgedProportional Hazards ModelsRisk FactorsSeverity of Illness IndexSmokingConceptsLung cancer risk factorsSystemic lupus erythematosusCancer risk factorsLung cancer casesLung cancer riskLung cancerRisk factorsSLE cohortDisease activityLupus erythematosusDrug exposureCancer casesCancer riskMcGill University Health CentreCumulative disease activityIncident lung cancerUniversity Health CentreCancer risk studiesInstitutional review boardHigher SLEDAIMedication exposureSLE controlsAdjusted effectHealth centersAdjusted model
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBreast NeoplasmsCohort StudiesFemaleHumansInternational CooperationLupus Erythematosus, SystemicMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk FactorsConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily historyDNA-damaging autoantibodies and cancer: the lupus butterfly theory
Noble PW, Bernatsky S, Clarke AE, Isenberg DA, Ramsey-Goldman R, Hansen JE. DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nature Reviews Rheumatology 2016, 12: 429-434. PMID: 27009542, DOI: 10.1038/nrrheum.2016.23.Peer-Reviewed Original ResearchAntibodies, AntinuclearAutoantibodiesAutoimmunityBiomarkersDNA DamageHumansLupus Erythematosus, SystemicNeoplasms
2015
DNA-dependent targeting of cell nuclei by a lupus autoantibody
Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports 2015, 5: 12022. PMID: 26156563, PMCID: PMC4496662, DOI: 10.1038/srep12022.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntinuclearAutoantibodiesCell Line, TumorCell NucleusDNAHumansLupus Erythematosus, SystemicProtein TransportSingle-Chain AntibodiesConceptsLupus anti-DNA autoantibodiesAnti-DNA autoantibodiesTumor cell nucleiSingle-chain variable fragmentPotential therapeutic applicationsLupus autoantibodiesTherapeutic approachesIschemic conditionsCertain cancer cellsChain variable fragmentCancer cellsCell nucleiAutoantibodiesNecrotic regionsVariable fragmentTherapeutic applicationsDNA damageNuclear uptakeScFvMalignancyGreater understandingTumorsStrokeDiseaseOptimizing a Lupus Autoantibody for Targeted Cancer Therapy
Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntinuclearDNA Breaks, Double-StrandedHCT116 CellsHumansLupus Erythematosus, SystemicNeoplasmsRecombinant Proteins
2014
Systemic Lupus Erythematosus and Malignancies A Review Article
Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S. Systemic Lupus Erythematosus and Malignancies A Review Article. Rheumatic Disease Clinics Of North America 2014, 40: 497-506. PMID: 25034158, DOI: 10.1016/j.rdc.2014.04.005.Commentaries, Editorials and LettersMeSH KeywordsComorbidityEarly Detection of CancerHumansImmunosuppressive AgentsIncidenceLupus Erythematosus, SystemicNeoplasmsResearchRisk FactorsConceptsSystemic lupus erythematosus populationRisk of lymphomaSystemic lupus erythematosusCancer risk profileHormone-sensitive cancersLung cancer riskRisk of cancerImmunosuppressive medicationsCervical dysplasiaLupus erythematosusDecreased riskSimilar pathophysiologyCancer riskHepatic carcinomaSLERisk profileRecent dataRiskHigh rateCancerReview articleErythematosusMedicationsLupusCarcinoma
2013
Breast Cancer in Systemic Lupus Erythematosus
Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast Cancer in Systemic Lupus Erythematosus. Oncology 2013, 85: 117-121. PMID: 23887245, PMCID: PMC3934367, DOI: 10.1159/000353138.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusSLE durationHistological typeBreast cancerDuctal carcinomaSLE cohortLupus erythematosusMultivariate logistic regression analysisDuctal histological typeIndependent risk factorCommon histological typeBreast cancer riskLogistic regression analysisRegression analysisLobular adenocarcinomaIndependent predictorsMixed histologyCancer RegistryRisk factorsHistological statusCancer riskCarcinomaHistology informationCancerCancer dates
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise role